Zynerba Pharmaceuticals Inc
F:6ZY
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Zynerba Pharmaceuticals Inc
Accrued Liabilities
Zynerba Pharmaceuticals Inc
Accrued Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accrued Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Z
|
Zynerba Pharmaceuticals Inc
F:6ZY
|
Accrued Liabilities
$9m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
13%
|
CAGR 10-Years
N/A
|
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Accrued Liabilities
$32.3B
|
CAGR 3-Years
5%
|
CAGR 5-Years
3%
|
CAGR 10-Years
10%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Accrued Liabilities
$13.1B
|
CAGR 3-Years
8%
|
CAGR 5-Years
6%
|
CAGR 10-Years
12%
|
|
|
|
Pfizer Inc
NYSE:PFE
|
Accrued Liabilities
$3.6B
|
CAGR 3-Years
2%
|
CAGR 5-Years
1%
|
CAGR 10-Years
4%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Accrued Liabilities
$14.4B
|
CAGR 3-Years
2%
|
CAGR 5-Years
2%
|
CAGR 10-Years
3%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Accrued Liabilities
$19.8B
|
CAGR 3-Years
26%
|
CAGR 5-Years
24%
|
CAGR 10-Years
19%
|
|
Zynerba Pharmaceuticals Inc
Glance View
Zynerba Pharmaceuticals, Inc. engages in the provision of pharmaceutically-produced transdermal cannabinoid therapies. The company is headquartered in Devon, Pennsylvania and currently employs 28 full-time employees. The company went IPO on 2015-08-05. Cannabinoids are a class of compounds derived from Cannabis plants. Its two primary cannabinoids contained in cannabis are cannabidiol and tetrahydrocannabinol (THC). The firm is developing Zygel, the pharmaceutically produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery and manufactured without the presence of THC. Zygel is being developed as a clear gel with once- or twice-daily dosing and is targeting the treatment of behavioral symptoms of FXS, ASD and 22q. The company has evaluated Zygel targeting the reduction of seizures in patients with a heterogeneous group of rare and ultra-rare epilepsies known as developmental and epileptic encephalopathies (DEE).
See Also
What is Zynerba Pharmaceuticals Inc's Accrued Liabilities?
Accrued Liabilities
9m
USD
Based on the financial report for Jun 30, 2023, Zynerba Pharmaceuticals Inc's Accrued Liabilities amounts to 9m USD.
What is Zynerba Pharmaceuticals Inc's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 5Y
13%
Over the last year, the Accrued Liabilities growth was 14%. The average annual Accrued Liabilities growth rates for Zynerba Pharmaceuticals Inc have been -1% over the past three years , 13% over the past five years .
